DUBLIN — On January 25, the U.S. Food and Drug Administration (FDA) approved NARCAN® Nasal Spray as a 2 mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. The 2 mg dose is approved for use in opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where ...
from EMS via xlomafota13 on Inoreader http://ift.tt/2jVVfqc
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
These concepts will yield more prepared, capable and resilient communities from EMS via xlomafota13 on Inoreader https://ift.tt/2PRIixV
-
Publication date: Available online 15 March 2018 Source: The Journal of Emergency Medicine Author(s): Eric J. Rebich, Stephanie S. Lee, J...
-
Introduction Over the last five years, the American Association for the Surgery of Trauma (AAST) has developed grading scales for Emergency ...
-
Objectives: To develop and validate an abbreviated version of the Cognitive Failure Questionnaire that can be used by patients as part of s...
-
Abstract Objectives To develop a patient decision aid to promote shared decision-making for stable, alert patients who present to the em...
-
Background: There has been little systematic examination of variation in pediatric burn care clinical practices and its effect on outcomes. ...
-
Background Hemostatic resuscitation principles have significantly changed adult trauma resuscitation over the past decade. Practice patterns...
-
Abstract Introduction The purpose of this study was to investigate the effects of alcohol intoxication in trauma patients in regard to its...
-
JAMA Internal Medicine from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2vJsoKB
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου